RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Total Current Liabilities
All obligations due within one year.
RenovoRx, Inc.NASDAQ: RNXT
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 10.6% from a year ago
Total current liabilities stood at $1.92M at the end of Q1 FY2026, up 10.6% from a year earlier and down 2.1% from the prior quarter. Over 3 fiscal years it compounded at +21.2% a year.
Context
- Total current liabilities amounted to 13.7% of total assets at the end of Q1 FY2026, up 2.9 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +10.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.96M USD
- Year-over-year change
- +2.8%
- 4-year CAGR
- +20.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.96M | +2.8% |
| FY2024 | 2024-12-31 | 1.91M | +62.5% |
| FY2023 | 2023-12-31 | 1.18M | +6.6% |
| FY2022 | 2022-12-31 | 1.1M | +17.5% |
| FY2021 | 2021-12-31 | 938K | — |
Total Current Liabilities vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's Mar 2026 total current liabilities of $1.92M is the lowest of the 6 companies compared; the peer median is $7.05M.
- Its year-over-year change of +10.6% is the 4th highest of 6, against a peer median of +25.0%.
- Total current liabilities amounts to 13.7% of total assets for RNXT, versus a peer median of 52.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $80.76M | +50.4% | +9.2% | 75.2% | |
| Mar 2026 | $12.79M | +410.7% | -22.1% | 78.7% | |
| Mar 2026 | $7.05M | -43.1% | -3.3% | 36.8% | |
| Mar 2026 | $6.32M | +25.0% | +21.3% | 17.9% | |
| Mar 2026 | $3.78M | -11.9% | +1071.7% | 52.3% | |
| Mar 2026 | $1.92M | +10.6% | +21.2% | 13.7% | |
| Peer median (excluding RNXT) | $7.05M | +25.0% | +9.2% | 52.3% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.